Meta-Analysis of the Efficacy and Safety of P2Y
BACKGROUND: Guidelines recommend dual antiplatelet therapy (DAPT) following drug-eluting stent (DES) placement for ≥12 months in acute coronary syndrome or 6 months in stable coronary artery disease. However, with the advent of newer-generation stents, the optimal duration of DAPT to balance bleeding and thrombotic risks has been debated.
OBJECTIVES: We aimed to perform a meta-analysis of randomized controlled trials (RCT) comparing P2Y
METHODS: Electronic databases were searched for RCTs of patients undergoing percutaneous coronary intervention (PCI) with DES placement who received short (≤ 3 months) vs. standard DAPT course (≥12 months) and were followed for ≥12-months. Rates of major adverse cardiovascular events (a composite of cardiovascular mortality, non-fatal myocardial infarction, and non-fatal stroke) were the primary outcome. Study-specific odds ratios (OR) and corresponding 95% confidence intervals were calculated using random-effects model.
RESULTS: A total of 20,706 patients (10,344 in the SDG and 10,362 in the STG) were analysed from four studies. There was no significant difference observed for MACE (OR = 0.95, 95% CI: 0.81-1.08, P = .92, I
CONCLUSION: A short duration of DAPT followed by P2Y
Cardiovasc Revasc Med
Elzanaty, A., Nazir, S., Awad, M., Elsheikh, E., Ahuja, K., donato, a., & Eltahawy, E. (2020). Meta-Analysis of the Efficacy and Safety of P2Y. Cardiovasc Revasc Med, 21 (12), 1500-1506. https://doi.org/10.1016/j.carrev.2020.05.012